Adcendo, a biopharma company developing antibody-drug conjugates for cancer treatment, has secured $75 million in a Series C financing round led by Jeito Capital. This funding, from Jeito's second fund which closed at $1.23 billion, will advance Adcendo's pipeline of first-and best-in-class ADCs. The company aims to address cancers with high unmet medical need.